Molecular Mode of Action of TRAIL Receptor Agonists—Common Principles and Their Translational Exploitation
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its death receptors TRAILR1/death receptor 4 (DR4) and TRAILR2/DR5 trigger cell death in many cancer cells but rarely exert cytotoxic activity on non-transformed cells. Against this background, a variety of recombinant TRAIL variant...
Main Author: | Harald Wajant |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/7/954 |
Similar Items
-
Receptor Oligomerization and Its Relevance for Signaling by Receptors of the Tumor Necrosis Factor Receptor Superfamily
by: Kirstin Kucka, et al.
Published: (2021-02-01) -
The role of the TNF receptors and apoptosis inducing ligands in tumor growth
by: O. H. Minchenko1, et al.
Published: (2016-10-01) -
Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation
by: Qiao Chunxia, et al.
Published: (2012-07-01) -
TWEAK/Fn14 axis: a promising target for the treatment of cardiovascular diseases.
by: Luis Miguel Blanco-Colio
Published: (2014-01-01) -
Apoptosis-Inducing TNF Superfamily Ligands for Cancer Therapy
by: Olivia A. Diaz Arguello, et al.
Published: (2021-03-01)